Keyes Jason A 4
4 · Equillium, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Keyes Jason A
Chief Financial Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-14−90,000→ 0 totalExercise: $2.45Exp: 2029-12-09→ Common Stock (90,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-14+100,000→ 100,000 totalExercise: $0.79Exp: 2031-01-03→ Common Stock (100,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-14+175,000→ 175,000 totalExercise: $0.79Exp: 2033-01-02→ Common Stock (175,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-14−175,000→ 0 totalExercise: $1.06Exp: 2033-01-02→ Common Stock (175,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-14+70,000→ 70,000 totalExercise: $0.79Exp: 2029-02-12→ Common Stock (70,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-14−70,000→ 0 totalExercise: $2.45Exp: 2029-02-12→ Common Stock (70,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-14+90,000→ 90,000 totalExercise: $0.79Exp: 2029-12-09→ Common Stock (90,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-14−100,000→ 0 totalExercise: $5.03Exp: 2031-01-03→ Common Stock (100,000 underlying) - Award
Employee Stock Option (right to buy)
2025-02-14+125,000→ 125,000 totalExercise: $0.79Exp: 2032-01-18→ Common Stock (125,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2025-02-14−125,000→ 0 totalExercise: $3.86Exp: 2032-01-18→ Common Stock (125,000 underlying)
Footnotes (2)
- [F1]Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
- [F2]On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.